Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer

BJU International

Volumn 92, Issue 9, 2003, Pages 911-914

  Friedrich, M G ^a,b   Toma, M I ^a   Hellstern, A ^a   Pantel, K ^a   Weisenberger, D J ^a   Noldus, J ^a   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder carcinoma; FISH; Noninvasive detection

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BTA STAT TEST; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; NMP 22 TEST; PRIORITY JOURNAL; URINALYSIS; UROGENITAL TRACT TUMOR;

ANEUPLOIDY; CARCINOMA, TRANSITIONAL CELL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 0346119096     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04528.x     Document Type: Article

References (23)

1. Badalament RA, Fair WR, Whitmore WF, Melamed MR. The relative value of cytometry and cytology in the management of bladder cancer. Semin Urol 1988; 6: 22-30
2. Lokeschwar VB, Soloway MS. Current bladder tumor tests: Does their projected utility fulfill clinical necessity? J Urol 2001; 165: 1067-77
3. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-11
4. Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159: 389-92
5. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt. A new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999; 161: 1486-9
6. Friedrich MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer. J Urol 2000; 163: 1039-42
7. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-62
8. Schneider A, Borgnat S, Lang H et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 2000; 60: 4617-22
9. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164: 1768-75
10. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors. 5th edn. New York: Wiley and Sons, 1997
11. Klaen R, Huland E, Baisch H, Huland H. Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486p3/12 in 241 unselected patients with bladder carcinoma. J Urol 1991; 145: 495-7
12. Leyh H, Marberger M, Conort P et al. Comparison of the BTA-Stat test with voided urine and bladder wash cytology in diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35: 52-6
13. Boman H, Hedelin H, Holmäng S. Four bladder tumor markers have a disappointing sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-3
14. Ponsky LE, Sharma S, Pandrangi L et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001; 166: 75-8
15. Raitanen MP, Kaasinen E, Lukkarinen O et al. and the Finnbladder Group. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology 2001; 57: 680-4
16. Seripa D, Parrella P, Gallucci M et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 2001; 95: 364-9
17. Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000; 85: 614-7
18. Ishiwata S, Takahashi S, Homma Y et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001; 57: 811-5
19. Halling KC, King W, Sokolova IA et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167: 2001-6
20. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multitarget fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 1950-4
21. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002; 42: 547-52
22. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001; 116: 79-86
23. Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol 2003; 43: 146-51